We conclude that the inclusion of DDR genes other than BRCA1/2 shared by both cancers considerably increases the detection rate of potentially actionable variants, which are triplicated in pancreatic and almost doubled in prostate cancer. This evidence concerns the gene BRCA1 and prostate cancer.